Skip to main content
PEGASUS MERCANTILE INC. logo

PEGASUS MERCANTILE INC. — Investor Relations & Filings

Ticker · LOAN ISIN · CA70557Y2042 LEI · 529900BGK3BYC4VSF690 CSE Financial and insurance activities
Open in API
Filings indexed 424 across all filing types
Latest filing 2024-04-03 Regulatory Filings
Country CA Canada
Listing CSE LOAN

About PEGASUS MERCANTILE INC.

https://xtacytherapeutics.com/

Pegasus Mercantile Inc. is a diversified venture capital firm and prospect generator that provides financial, operational, and management assistance to high-growth companies. The firm specializes as an incubator for early-stage investments within the wellness consumer goods market, focusing on biotechnology, hemp, CBD, functional mushrooms, and psychedelics. Its investment strategy targets solutions for chronic pain, depression, and mental illness, often utilizing pioneering techniques such as micro-dosing organic and synthetic compounds. Pegasus Mercantile assists portfolio companies from startup through commercialization, specializing in navigating complex regulatory requirements, including clinical trials, patenting, and legislative approvals. The firm also provides debt financing facilities.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the extension of a Management Cease Trade Order (MCTO) issued by the British Columbia Securities Commission. It references the company's failure to file certain continuous disclosure documents, including annual audited financial statements, interim financial statements, and Management Discussion and Analysis (MD&A) reports. The document states expected filing dates for these reports but does not contain the reports themselves or substantive financial data. It is an announcement about regulatory compliance status and filing delays rather than the actual financial reports or certifications. The document length is 4315 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-04-03 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a bi-weekly status update regarding a Management Cease Trade Order (MCTO) issued by the British Columbia Securities Commission due to the company's delay in filing its audited annual financial statements and related documents. It references regulatory compliance under National Policy 12-203 and provides updates on the status of the filing delay and the MCTO. The document does not contain actual financial statements or detailed financial data but is a regulatory update about the company's filing status and trading restrictions on management. It is not the annual report itself, nor an earnings release or management discussion. It fits best as a Regulatory Filing (RNS) because it is a compliance-related announcement and status update that does not fit other specific categories.
2024-03-15 English
News release - English.pdf
Regulatory Filings
2024-02-29 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a bi-weekly status update regarding a Management Cease Trade Order (MCTO) issued by the British Columbia Securities Commission due to the company's delay in filing its audited annual financial statements and related documents. It references regulatory compliance and ongoing disclosure obligations under National Policy 12-203. The document does not contain the actual financial statements or detailed financial data but is an update on the regulatory status and filing delays. It is not an annual report, audit report, or interim report, nor is it a certification or officer attestation. It is a regulatory announcement related to compliance and filing status, fitting best under Regulatory Filings (RNS).
2024-02-14 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is an announcement by Xtacy Therapeutics Corp. regarding a Letter of Intent (LOI) with AVM Biotechnology for a potential acquisition and financing arrangements. It includes details about the proposed convertible loan and private placement, as well as a corporate update about a Management Cease Trade Order due to missed filing deadlines for audited annual financial statements. The document does not contain actual financial statements or detailed financial analysis but rather provides an update on corporate transactions and regulatory compliance status. It is not a full annual report, audit report, or interim report. The primary content is about a financing and acquisition update and a regulatory compliance announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-02-07 English
News release - English.pdf
Regulatory Filings
2024-01-31 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.